Nutriflex Omega Special Zonder Elektrolyten (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The blend supplies the building blocks required for protein synthesis and activates the mTOR pathway, which promotes cellular growth and tissue repair. By delivering these substrates directly, it helps maintain nitrogen balance and supports metabolic functions in catabolic states.

The prescribed dose is individualized by the treating clinician based on the patient’s nutritional assessment, weight, renal and hepatic function, and overall clinical condition. Healthcare professionals calculate the appropriate volume and infusion rate to meet specific protein and amino acid requirements.

Safety data for this amino acid mixture in pregnancy or lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nutriflex Omega Special offers a comprehensive profile of both essential and non‑essential amino acids without added electrolytes, which can be advantageous when electrolyte balance is managed separately. Compared with simpler single‑amino‑acid formulations, it provides broader support for protein synthesis and metabolic needs in critically ill patients.

The product should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperature fluctuations. Once opened, follow the manufacturer’s guidance on stability and use within the recommended time frame.

It is administered intravenously as an infusion, typically diluted in a compatible carrier solution. The infusion rate and total daily volume are determined by the prescribing clinician according to the patient’s nutritional goals and tolerance.

Serious risks include severe hypersensitivity reactions, metabolic acidosis, hyperammonemia in patients with liver dysfunction, and catheter‑related complications such as infection or thrombosis. Continuous monitoring during infusion helps detect and manage these events promptly.

Patients with known hypersensitivity to any component of the formulation, those with uncontrolled metabolic disorders, severe hepatic or renal impairment without dose adjustment, and individuals receiving incompatible concurrent therapies should avoid using this product unless specifically directed by a healthcare professional.